The global connected drug delivery devices market size reached US$ 652.9 Million in 2022. Looking forward, the publisher expects the market to reach US$ 3,517.0 Million by 2028, exhibiting a growth rate (CAGR) of 32.4% during 2022-2028.
Connected drug delivery devices are smart wireless electronic systems used to support patient supervision and counseling in home settings. They are equipped with dose reminders, adherence trackers, sensors and monitoring tools to provide instant feedback and education tools for personalized patient care. They are convenient and save costs associated with clinic-based treatment. Consequently, connected drug delivery devices are widely used in the remote monitoring of patients with asthma, diabetes, hepatitis C, hypertension, tuberculosis, multiple sclerosis, clinically isolated syndrome, chronic obstructive pulmonary disease (COPD), and liver and renal transplant recipients.
The rapidly increasing cost of medical management and the rising need to improve patient treatment outcomes are among the main factors catalyzing the demand for connected drug delivery devices. Besides this, a shift in preferences towards home-based care is also stimulating the market growth. Moreover, the rising number of individuals suffering from chronic diseases, along with the increasing emphasis on preventive care, is influencing the market positively. Furthermore, the widespread adoption of connected devices in laboratories and hospitals for maintaining electronic health records (EHR) is driving the market growth. Apart from this, several manufacturers are offering devices that can connect to apps and programs, allow data transfer, enable automated tracking, and maximize patient safety. As they also provide access to real-time patient data, connected drug delivery devices are increasingly being utilized by biopharma companies for determining adherence improvement outcomes to regulators, payers, and patients.
Connected drug delivery devices are smart wireless electronic systems used to support patient supervision and counseling in home settings. They are equipped with dose reminders, adherence trackers, sensors and monitoring tools to provide instant feedback and education tools for personalized patient care. They are convenient and save costs associated with clinic-based treatment. Consequently, connected drug delivery devices are widely used in the remote monitoring of patients with asthma, diabetes, hepatitis C, hypertension, tuberculosis, multiple sclerosis, clinically isolated syndrome, chronic obstructive pulmonary disease (COPD), and liver and renal transplant recipients.
The rapidly increasing cost of medical management and the rising need to improve patient treatment outcomes are among the main factors catalyzing the demand for connected drug delivery devices. Besides this, a shift in preferences towards home-based care is also stimulating the market growth. Moreover, the rising number of individuals suffering from chronic diseases, along with the increasing emphasis on preventive care, is influencing the market positively. Furthermore, the widespread adoption of connected devices in laboratories and hospitals for maintaining electronic health records (EHR) is driving the market growth. Apart from this, several manufacturers are offering devices that can connect to apps and programs, allow data transfer, enable automated tracking, and maximize patient safety. As they also provide access to real-time patient data, connected drug delivery devices are increasingly being utilized by biopharma companies for determining adherence improvement outcomes to regulators, payers, and patients.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global connected drug delivery devices market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, end user and technology.Breakup by Product:
- Connected Sensors
- Connected Inhaler Sensors
- Connectable Injection Sensors
- Integrated Connected Devices
- Connected Inhalation Devices
- Connected Injection Devices
Breakup by End User:
- Hospitals and Healthcare Providers
- Homecare
Breakup by Technology:
- Bluetooth
- NFC
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
- The competitive landscape of the industry has also been examined along with the profiles of the key players being Adherium Ltd., BioCorp Production, Cohero Health Inc. (AptarGroup Inc.), Elcam Medical ACS. Ltd, Findair Sp. z o. o., Merck KGaA, Phillips Medisize (Molex LLC), Propeller Health (Resmed Inc.), Teva Pharmaceutical Industries Ltd., and West Pharmaceutical Services Inc.
Key Questions Answered in This Report:
- How has the global connected drug delivery devices market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global connected drug delivery devices market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the end user?
- What is the breakup of the market based on the technology?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global connected drug delivery devices market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Connected Drug Delivery Devices Market
6 Market Breakup by Product
7 Market Breakup by End User
8 Market Breakup by Technology
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Adherium Ltd.
- BioCorp Production
- Cohero Health Inc. (AptarGroup Inc.)
- Elcam Medical ACS. Ltd
- Findair Sp. z o. o.
- Merck KGaA
- Phillips Medisize (Molex LLC)
- Propeller Health (Resmed Inc.)
- Teva Pharmaceutical Industries Ltd.
- and West Pharmaceutical Services Inc.
Methodology
LOADING...
